BiotechTube

Placebo + Pirtobrutinib

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsing Multiple Sclerosis

Conditions

Relapsing Multiple Sclerosis, Multiple Sclerosis

Trial Timeline

May 1, 2024 → Feb 13, 2026

NCT ID
NCT06104683

About Placebo + Pirtobrutinib

Placebo + Pirtobrutinib is a phase 2 stage product being developed by Eli Lilly for Relapsing Multiple Sclerosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06104683. Target conditions include Relapsing Multiple Sclerosis, Multiple Sclerosis.

What happened to similar drugs?

20 of 20 similar drugs in Relapsing Multiple Sclerosis were approved

Approved (20) Terminated (2) Active (0)
✅Rebif® + Rebif®MerckApproved
✅Interferon beta-1a (Rebif)MerckApproved
✅Interferon beta-1aMerckApproved
✅Cladribine 10 mg oral tabletMerckApproved
✅Rebif® (clone 484-39)MerckApproved
✅RebifMerckApproved
✅Fingolimod 0.5 mgNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06104683Phase 2Withdrawn

Competing Products

20 competing products in Relapsing Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
LY2127399 + PlaceboEli LillyPhase 2
35
dirucotide + placeboEli LillyPhase 2/3
38
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
DaclizumabAbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccineAbbViePhase 2
35
BIIB019 (Daclizumab)AbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
40
Rebif (Interferon beta-1a)MerckPre-clinical
26
Interferon beta-1aMerckPre-clinical
26
Rebif New Formulation + prophylactic Ibuprofen + Rebif New Formulation + ibuprofen PRNMerckPhase 3
40
Rebif® + Avonex®MerckPhase 3
40
Rebif® + Rebif®MerckApproved
43
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) aloneMerckPhase 2
35
Placebo + IFN beta-1a + MethylprednisoloneMerckPhase 2
27
Interferon beta-1a (Rebif)MerckApproved
43
Teriflunomide + EvobrutinibMerckPhase 3
32
Cladribine + Placebo + Microgynon®MerckPhase 1
29
Rebif (Interferon beta-1a)MerckPre-clinical
26